Skip to main content
Premium Trial:

Request an Annual Quote

Sensigen Options Rights to Lupus Dx Biomarkers from Univ. of Michigan

NEW YORK (GenomeWeb News) — Sensigen has acquired an option from the University of Michigan to exclusively license a set of epigenetic biomarkers that can detect and monitor lupus, the company said this week.
 
The technology covered under the license is a panel of biomarkers of epigenetic variations of genes and related research assays linked to lupus, the company said.
 
These biomarkers were developed by Bruce Richardson, professor of medicine at the University of Michigan and the chief of rheumatology at Ann Arbor Veterans Hospital, who “discovered that the levels of methylation of certain genes were closely associated with the onset of lupus,” the company said.
 
Current methods for monitoring and detecting the autoimmune disease measure levels of antibodies and proteins known to fluctuate in the blood.
 
Richardson said that an assay using this panel and based on Sensigen’s AttoSense “has the potential to achieve an unprecedented level of diagnostic sensitivity and specificity” for diagnosing and managing lupus.
 
Financial terms of the agreement were not released.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.